6 results match your criteria: "Department of Medicine Stanford University School of Medicine Stanford CA USA.[Affiliation]"
Background: Little is known about how well trial participants with chronic kidney disease (CKD) represent real-world adults with CKD. We assessed the population representativeness of clinical trials supporting the 2021 Kidney Disease: Improving Global Outcomes blood pressure (BP) guidelines in real-world adults with CKD.
Methods And Results: Using a cross-sectional analysis, we identified patients with CKD who met the guideline definition of hypertension based on use of antihypertensive medications or sustained systolic BP ≥120 mm Hg in 2019 in the Veterans Affairs and Kaiser Permanente of Southern California.
Article Synopsis
- * In the ISCHEMIA trial, women had similar catheterization rates but significantly lower revascularization rates than men (73.4% vs. 81.2%, respectively).
- * Despite these differences, there were no significant disparities in primary outcomes like cardiovascular death and myocardial infarction between women and men, indicating that both sexes responded similarly to treatment.
Article Synopsis
- The study explores the link between major depressive disorder (MDD) and peripheral artery disease (PAD) using genetic analysis.
- It finds that a genetic predisposition to MDD is associated with a higher likelihood of developing PAD, influenced by factors like smoking, alcohol consumption, and body mass index.
- The results suggest that addressing both mental and physical health could be crucial in treating cardiovascular diseases effectively.
Design and Implementation of an Electronic Health Record-Integrated Hypertension Management Application.
J Am Heart Assoc
January 2024
Center for Digital Health, Department of Medicine Stanford University Stanford CA USA.
Article Synopsis
- * A hypertension management platform was developed through careful analysis of clinician workflows and needs, incorporating input from 5 Stanford clinicians and a team of 15 specialists across various fields.
- * The platform aims to enhance chronic disease management by integrating digital health tools, offering a model that can be adapted for other cardiovascular digital health solutions.
Sex-Specific Differences in Gα-Mediated Signaling Downstream of PTH1R Activation by Abaloparatide in Bone.
JBMR Plus
December 2022
Division of Endocrinology, Department of Medicine Stanford University School of Medicine Stanford CA USA.
Teriparatide, recombinant parathyroid hormone (PTH[1-34]), and abaloparatide, an analogue of PTH related-peptide (PTHrP[1-34]), are both anabolic medications for osteoporosis that target the PTH receptor PTH1R. PTH1R is a G protein-coupled receptor, and the stimulatory Gs protein is an important mediator of the anabolic actions of PTH1R activation in bone. We have published that mice lacking the α subunit of Gs in osteoprogenitors do not increase bone mass in response to PTH(1-34).
View Article and Find Full Text PDFControversies in Vitamin D: A Statement From the Third International Conference.
JBMR Plus
December 2020
Department of Medicine, Endocrinology Division, College of Physicians and Surgeons Columbia University New York NY USA.
The Third International Conference on Controversies in Vitamin D was held in Gubbio, Italy, September 10-13, 2019. The conference was held as a follow-up to previous meetings held in 2017 and 2018 to address topics of controversy in vitamin D research. The specific topics were selected by the steering committee of the conference and based upon areas that remain controversial from the preceding conferences.
View Article and Find Full Text PDF